IsoRay (NYSE:ISR) has inked a private placement deal worth approximately $8.3 million, according to an SEC filing posted this week. Through the deal, Richland, Wash.-based IsoRay is floating 11 million shares of common stock at 75¢ per share with several institutional and accredited investors, according to the filing. The company said it will also offer unregistered […]
IsoRay wins FDA nod for GammaTile brain tumor treatment
IsoRay (NYSE:ISR) said today it won FDA 510(k) clearance for its GammaTile brachytherapy technology designed for treating recurrent brain tumors. The Richland, Wash.-based company’s GammaTile is a radiation system using Cesium-131 radiation seeds embedded in a collagen ’tile’ which is designed to be placed in surgical margins at the time of surgery. IsoRay said it had […]
Dr. Gawande tapped to lead Amazon-JPM-Berkshire health play | Personnel Moves – June 21, 2018
The joint healthcare venture between Amazon (NSDQ:AMZN), Berkshire Hathaway and J.P. Morgan Chase said this week it named Brigham and Women’s Hospital surgeon, New Yorker magazine staff writer and bestselling author Dr. Atul Gawande as its CEO, effective July 9. The joint venture said that the newly formed company will be headquartered in Boston, and will operate […]
Zimmer Biomet prez, CEO Dvorak unexpectedly resigns | Personnel Moves, July 12, 2017
Zimmer Biomet (NYSE:ZBH) said late yesterday its prez and CEO David Dvorak has resigned from his position at the head of the company, effective immediately, to be replaced on an interim basis by senior VP and CFO Daniel Florin until a permanent successor is named. The Warsaw, Ind.-based company said it is retaining “a leading executive search […]
FDA requests more info on IsoRay’s GammaTile
IsoRay (NYSE:ISR) said today that the FDA requested additional data on the company’s pending 510(k) application for its GammaTile radiation therapy system. The Richland, Wash.-based company’s GammaTile is a radiation system using Cesium-131 radiation seeds embedded in a collagen ’tile’ which is designed to be placed in surgical margins at the time of surgery. “This is […]
Halyard Health taps former Acelity head Woody for CEO | Personnel Moves July 5, 2017
Halyard Health (NYSE:HYH) said late last month it tapped former Acelity prez & CEO Joseph Woody as its new chief executive officer, replacing a retiring Robert Abernathy. Woody will also assume a seat on the board of directors, with former CEO Abernathy continuing on as board chair, the Alpharetta, Ga.-based company said. “On behalf of the […]
IsoRay touts another ‘100%’ study
IsoRay (NYSE:ISR) today released data from a study of its Cesium-131 brachytherapy for treating patients with large brain metastases, touting a 100% freedom from local progression. Results from the study were published in the International Journal of Radiation Oncology, Biology, Physics, the Richland, Wash.-based company said. In the study, researchers assessed the impact of low-dose rate […]
Court OKs IsoRay’s $3.5m settlement
IsoRay (NYSE:ISR) said today that the US District Court for the Eastern District of Washington has approved a previously announced $3.5 million settlement related to a class action suit brought against it by shareholders last June. The Richland, Wash.-based company faced putative class-action lawsuits from investors, accusing the company of making false or misleading statements about a clinical trial of […]
Smith & Nephew pulls the trigger on planned CFO succession | Personnel Moves | January 20, 2017
Smith & Nephew (NYSE:SNN) said last week that CFO Julie Brown left the orthopedics & wound care company, after announcing her succession last July. Brown was named finance chief in November 2012 and assumed the role in February the following year. She is moving on to work as chief operating & financial officer for British luxury brand […]
IsoRay settles class action shareholders suit for $3.5m
IsoRay (NYSE:ISR) said it inked a $3.5 million settlement deal related to a class action suit brought against it by shareholders in June. The Richland, Wash.-based company is facing putative class-action lawsuits from investors, accusing the company of making false or misleading statements about a clinical trial of its Cesium 131 brachytherapy seeds designed to treat cancer in a press release […]
IsoRay touts brachytherapy brain cancer trial
IsoRay (NYSE:ISR) today released results from a prospective trial of intraoperative brachytherapy using its Cesium-131 brachytherapy seeds, touting that 95% of treated tumors showed no regrowth at the operative site. The study examined the use of the IsoRay’s seeds for treating recurrent aggressive meningiomas by applying seeds embedded in collagen tiles directly to brain tissue after […]
- 1
- 2
- 3
- 4
- Next Page »
MassDevice Network
@MassDevice
LinkedIn
Google+